News | July 29, 2007

Siemens Collaborates on Study of Imaging Biomarker to Detect Activity of Cancer Cells

July 30, 2007 – Siemens Medical Solutions announced today that it has been granted an Investigational New Drug (IND) Exemption by the U.S. Food and Drug Administration (FDA) to conduct a Phase I clinical trial of (F-18) 3'-fluoro-3'-deoxythymidine (FLT), a molecular imaging biomarker that has shown promise in monitoring the proliferation of cancer cells, which could help physicians quickly determine the effectiveness of cancer therapies.

To broaden the scope of FLT research, Siemens will support the FLT Phase I clinical trial that will be conducted at Memorial Sloan-Kettering Cancer Center located in New York City, with whom Siemens has signed a research collaboration agreement focused on the codevelopment of imaging biomarkers that will be used in PET imaging. Through these collaborative efforts, Siemens intends not only to make FLT more readily accessible to research and academic institutions for further study, but also to continue research into new more target specific imaging biomarkers for PET.

The significance of FLT is that it may be able to allow researchers and physicians to detect the rate of the proliferation of cancerous cells through a molecular imaging technique like PET-CT (positron emission tomography-computed tomography), by enabling visualization of key steps in the replication of DNA, which precedes cell division. By enabling the imaging of the biological processes within cancer cells, FLT could help physicians to personalize cancer therapies by more quickly assessing cancer therapies, avoiding ineffective therapies and determining the most appropriate treatment for an individual patient.

For more information: www.usa.siemens.com/medical

Related Content

PET Tracer Gauges Effectiveness of Promising Alzheimer's Treatment

Longitudinal PET imaging with 18F-AV45. PET imaging shows the average 18F-AV45 uptake per animal group at 8 and 13 months of age. A significant interaction of genotype treatment was observed in the cortex (p = 0.0248), hippocampus (p = 0.0071) and thalamus (p = 0.0084), indicating reduced [18F]-AV45 uptake in BACE1 inhibited transgenic mice. Credit: MICA, University of Antwerp, Belgium.

News | Radiopharmaceuticals and Tracers | December 28, 2017
In the December featured basic science article in The Journal of Nuclear Medicine, Belgian researchers report on the...
Michael J. Fox Foundation and Tau Consortium Developing PET Tracers for Neurodegenerative Disease
News | Radiopharmaceuticals and Tracers | October 27, 2017
The Michael J. Fox Foundation for Parkinson's Research (MJFF) and the Tau Consortium announced a funding partnership to...
SNMMI Publishes New FDG PET/CT Appropriate Use Criteria
News | PET-CT | October 25, 2017
The Society of Nuclear Medicine and Molecular Imaging (SNMMI) has published appropriate use criteria (AUC) for FDG PET/...
Majority of Recurrent Prostate Cancer Patients' Treatment Plan Changed Following Fluciclovine 18F PET/CT
News | Prostate Cancer | October 04, 2017
Blue Earth Diagnostics recently announced the results of a pre-planned interim analysis from an investigational...
Toshiba Highlights Latest CT Advancements at RSNA 2017
News | Computed Tomography (CT) | September 18, 2017
Toshiba Medical announced that it will display several new enhancements to its existing computed tomography (CT)...
Double Targeting Ligands to Identify and Treat Prostate Cancer

The mice were imaged with small-animal PET/CT using 124I-RPS-027 (7.4 MBq [200 μCi]). Credit: JM Kelly et al., Department of Radiology, Weill Cornell Medicine, New York, NY

News | Prostate Cancer | September 14, 2017
Researchers have demonstrated a new, effective way to precisely identify and localize prostate cancer tumors while...
Blue Earth Diagnostics Announcing Results of FALCON PET/CT Trial at ASTRO 2017
News | PET-CT | September 13, 2017
September 13, 2017 — Blue Earth Diagnostics announced the upcoming oral presentation of initial results from the FALC
FDG-PET/CT Predicts Melanoma Patients' Response to Immune Checkpoint Inhibitor Therapy
News | PET-CT | September 07, 2017
September 7, 2017 — Advanced melanoma has a poor prognosis, but immune checkpoint inhibitor therapy can be effective
Videos | Nuclear Imaging | August 24, 2017
Prem Soman, M.D., director of nuclear cardiology at the Heart and Vascular Institute, University of Pittsburgh, and p
ASNC and SNMMI Release Joint Document on Diagnosis, Treatment of Cardiac Sarcoidosis
News | Cardiac Imaging | August 18, 2017
August 18, 2017 — The American Society of Nuclear Cardiology (ASNC) has released a joint expert consensus document wi
Overlay Init